Proprietary Targeted Radiopharmaceuticals Lie at the Heart of Perspective's Therapies
Our radiopharmaceuticals have four components: the radioisotope, the cell-targeting peptide, the chelator, and the linker. Proprietary structural modifications are made to each molecule to optimize stability, tumor targeting, tumor accumulation, drug pharmacokinetics, and clearance.
- The cell-targeting peptide is selected for high affinity and specificity
- The chelator has been customized especially for Pb, enabling stable radiolabelling without leakage and ensure rapid renal clearance by carrying a net-zero charge
- The linker is selected to assist peptide binding and optimize clearance from blood and healthy tissues